CureVac N.V. (CVAC)

102.69 +1.62 (+1.60%) At close: 4:00PM EST

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
http://www.curevac.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 500

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Franz-Werner Haas L.L.M., Ph.D., LL.M.	CEO, COO & Member of Exec. Board	N/A	N/A	1970
Dr. Florian von der Mulbe M.B.A., Ph.D., MBA	Co-Founder, Member of Exec. Board, Chief Production Officer	N/A	N/A	1973
Mr. Pierre Kemula B.Sc.	CFO & Member of Exec. Board	N/A	N/A	1974
Ms. Mariola Fotin-Mleczek	CTO & Member of Exec. Board	N/A	N/A	1967
Ms. Ulrike Gnad-Vogt	Chief Medical Officer & Member of Exec. Board	N/A	N/A	N/A
Dr. Igor Splawski M.Sc., Ph.D.	Chief Scientific Officer	N/A	N/A	1968
Mr. Matthew L. S. Beck	VP of Investor Relations	N/A	N/A	N/A
Mr. Thorsten Schüller	Head of Corp. Communications	N/A	N/A	N/A
Slavica Stevanovic-Heck	Head of HR	N/A	N/A	N/A
Dr. Ingmar Hoerr	Co-Founder, CEO & Supervisory Board Chairman (Leave of Absence)	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate governance

CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.